CD28 and breast cancer: This setup allowed us to observed that when CD3/CD28-stimulated PBMCs were added to spheroids of the BC cell line MDA-MB-231 (23), led to a decrease in tumor cell viability, an effect dependent on the frequency of HLA-DR-expressing CTLs within the PBMCs (Figure 1B).